<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01952223</url>
  </required_header>
  <id_info>
    <org_study_id>GETUG-AFU 23 - UC-0160/1202</org_study_id>
    <secondary_id>2012-000566-38</secondary_id>
    <nct_id>NCT01952223</nct_id>
  </id_info>
  <brief_title>A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse</brief_title>
  <acronym>PEACE2</acronym>
  <official_title>A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the effect of neoadjuvant cabazitaxel and pelvic&#xD;
      radiotherapy in combination with androgen deprivation therapy (ADT)-radiotherapy on clinical&#xD;
      progression-free survival in patients with high-risk localized prostate cancer (with a&#xD;
      stringent selection of patients with at least 2 high-risk features), in a 2 by 2 factorial&#xD;
      trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients can be randomized via the TENALEA web site process that insure&#xD;
      centralization of the randomization.&#xD;
&#xD;
      Randomization will be performed according a 1:1:1:1 ratio. The randomization will be&#xD;
      stratified (by minimization) according to the number of risk factors (2 vs.3), disease extent&#xD;
      (pN- vs. pN+ vs. pNx) and the site.&#xD;
&#xD;
      The minimization will be defined with a similar weight for all 3 stratification factors and a&#xD;
      probability of assigning the treatment that minimize the imbalance equal to 80%.&#xD;
&#xD;
      The main analysis of progression-free survival (PFS) will be event driven (&gt; 247 events). It&#xD;
      will likely be performed when the median follow-up is approximately 6 years, i.e. 4 years&#xD;
      after the inclusion of the last patient (assuming an accrual of 4 years).&#xD;
&#xD;
      A long-term analysis (allowing for robust PFS and overall survival (OS) data) will also be&#xD;
      performed when the follow-up is approximately 10 years. Its exact timing will be discussed&#xD;
      with the steering committee and the IDMC.&#xD;
&#xD;
      An interim analysis of the primary endpoint is planned. This interim analysis will be&#xD;
      performed at a 0.001 level (Peto) after 50% of the events i.e. 125 have occurred.&#xD;
&#xD;
      For each comparison (CT comparison and pelvic RT comparison) the two PFS curves will be&#xD;
      compared using the adjusted logrank test (bilateral test): adjusted logrank on pelvic RT for&#xD;
      the CT comparison and on CT for the pelvic RT comparison. A multivariate analysis using the&#xD;
      Cox model will also be used.&#xD;
&#xD;
      An Independent Data Monitoring Committee (IDMC) composed of international experts (at least 2&#xD;
      physicians and 1 statistician) will be selected.&#xD;
&#xD;
      For safety purpose, the IDMC will meet after the inclusion of 20 patients (and then again&#xD;
      after accrual of 50 patients) in the cabazitaxel and pelvic radiotherapy arm, to assess&#xD;
      tolerance, (i.e. after the inclusion of approximately 80 and then 200 patients in the trial).&#xD;
      Depending on the results of this feasibility phase and of any new relevant clinical results&#xD;
      in such a population, the remaining patients (n=848) will be enrolled.&#xD;
&#xD;
      During this second phase, the IDMC will then meet every two years approximately during&#xD;
      accrual to carefully assess accrual rate and toxicity and examine the efficacy interim&#xD;
      analysis results in the light of the results of similar trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Anticipated">July 2041</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>prostate-specific antigen response at 3 months</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biochemical progression-free survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metastases-free survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local relapse-free survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prostate cancer-specific survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute toxicity</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of treatment on serum testosterone</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>long-term toxicity</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>predictive biomarkers of treatment efficacy</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">761</enrollment>
  <condition>Adenocarcinoma of Prostate</condition>
  <condition>Progression of Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>ADT + pelvic RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADT for a total duration of 3 years i.e. luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist +/-Peripheral anti-androgen&#xD;
Pelvic RT (by IMRT or IGRT protocol):&#xD;
Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)&#xD;
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADT + Cabazitaxel + prostate RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADT Cabazitaxel: 4 CT cycles&#xD;
Prostate-only RT (IMRT or IGRT):&#xD;
Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)&#xD;
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADT + cabazitaxel + pelvic RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADT Cabazitaxel: 4 CT cycles&#xD;
Pelvic RT (IMRT or IGRT):&#xD;
Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)&#xD;
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADT + prostate radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ADT for a total duration of 3 years: LHRH agonist or LHRH antagonist +/- anti-androgen&#xD;
Prostate-only RT (IMRt or IGRT):&#xD;
Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)&#xD;
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel</intervention_name>
    <description>Cabazitaxel administered at 25 mg/mÂ² as a 1 hour intravenous infusion every 3 weeks (1 cycle = 21 days) for 4 cycles</description>
    <arm_group_label>ADT + Cabazitaxel + prostate RT</arm_group_label>
    <arm_group_label>ADT + cabazitaxel + pelvic RT</arm_group_label>
    <other_name>jevtana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Pelvic radiotherapy</intervention_name>
    <description>Prostate+pelvic RT (2 Gy fractions, 5 times per week):&#xD;
Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)&#xD;
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy</description>
    <arm_group_label>ADT + cabazitaxel + pelvic RT</arm_group_label>
    <arm_group_label>ADT + pelvic RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>prostate radiotherapy</intervention_name>
    <description>Prostate-only RT (2 Gy fractions, 5 times per week):&#xD;
Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)&#xD;
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy</description>
    <arm_group_label>ADT + Cabazitaxel + prostate RT</arm_group_label>
    <arm_group_label>ADT + prostate radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Any T histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          2. No clinically or radiologically suspected metastases, including no enlarged pelvic&#xD;
             lymph nodes (&gt; 1 cm in small diameter)&#xD;
&#xD;
          3. Gleason score â¥ 6&#xD;
&#xD;
          4. Meets at least 2 of the following criteria for high-risk:&#xD;
&#xD;
               -  Gleason score â¥ 8&#xD;
&#xD;
               -  T3 or T4 disease (T3 defined by MRI is acceptable)&#xD;
&#xD;
               -  Prostate-specific antigen equal or greater than 20 ng/mL&#xD;
&#xD;
          5. No prior treatment for prostate cancer except lymph node dissection (patients with pN-&#xD;
             and pN+ disease can be accrued) or ADT (started up to 6 weeks before randomization).&#xD;
&#xD;
          6. 18 years â¤ Age â¤ 75 years&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) 0-1 performance status&#xD;
&#xD;
          8. Expected life expectancy of more than 10 years&#xD;
&#xD;
          9. Absolute neutrophil count â¥ 1.5 x 10â¹/L&#xD;
&#xD;
         10. Platelets â¥ 100 x 10â¹/L&#xD;
&#xD;
         11. Hb â¥ 9.0 g/dL&#xD;
&#xD;
         12. Hepatic function: serum bilirubin â¤ 1 upper limit of normal (ULN); aspartate&#xD;
             aminotransferase (AST) and alanine aminotransferase (ALT) â¤ 2.5 x ULN&#xD;
&#xD;
         13. Renal function (creatinine clearance using the Chronic Kidney Disease Epidemiology&#xD;
             group (CKD-EPI) formula â¥ 60 mL/min).&#xD;
&#xD;
         14. Potentially reproductive patients must agree to use an effective contraceptive method&#xD;
             while on treatment and for 6 months after the final dose of investigational product.&#xD;
&#xD;
         15. Patients must be affiliated to a Social Security System or should fulfill the country&#xD;
             legislation for clinical trials.&#xD;
&#xD;
         16. Patients who have received the information sheet and signed the informed consent form.&#xD;
&#xD;
         17. Patients must be willing and able to comply with scheduled visits, treatment plan,&#xD;
             laboratory tests and other study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with other known concurrent severe and/or uncontrolled medical disease which&#xD;
             could compromise participation in the study, such as:&#xD;
&#xD;
               1. infection,&#xD;
&#xD;
               2. cardiac disease such as uncontrolled hypertension, congestive cardiac failure,&#xD;
                  ventricular arrhythmias, active ischemic heart disease, myocardial infarction&#xD;
                  within one year, left ventricular ejection fraction (LVEF) &gt; grade 2,&#xD;
&#xD;
               3. uncontrolled diabetes mellitus,&#xD;
&#xD;
               4. current active hepatic or biliary disease (with exception of subjects with&#xD;
                  Gilbert's syndrome, asymptomatic gallstones, stable chronic liver disease per&#xD;
                  investigator assessment),&#xD;
&#xD;
               5. renal disease,&#xD;
&#xD;
               6. active GI tract ulceration, malabsorption syndrome, disease significantly&#xD;
                  affecting gastrointestinal function, or resection of the stomach or small bowel.&#xD;
                  Subjects with active, uncontrolled ulcerative colitis are also excluded,&#xD;
&#xD;
               7. known severely impaired lung function (spirometry and diffusing capacity of the&#xD;
                  lungs for carbon monoxide (DLCO) 70% or less of normal and O2 saturation of 88%&#xD;
                  or less at rest on room air).&#xD;
&#xD;
          2. Other prior malignancy within the last 5 years, except basal cell skin cancer&#xD;
&#xD;
          3. Physical or psychological condition that would preclude study compliance&#xD;
&#xD;
          4. Hypersensitivity to cabazitaxel (hypersensitivity reaction â¥grade 3), to other&#xD;
             taxanes, or to any excipients of the formulation including polysorbate 80&#xD;
&#xD;
          5. Patients with significantly altered mental status prohibiting the understanding of the&#xD;
             study or with psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule; those&#xD;
             conditions should be discussed with the patient before registration in the trial.&#xD;
&#xD;
          6. Patients who received any other investigational drugs within the 30 days prior to the&#xD;
             start of cabazitaxel.&#xD;
&#xD;
          7. Previous pelvic irradiation that make prostatic irradiation impossible&#xD;
&#xD;
          8. Severe GI disorders precluding pelvic irradiation&#xD;
&#xD;
          9. Patients already included in another therapeutic trial involving an experimental drug&#xD;
&#xD;
         10. Individual deprived of liberty or placed under the authority of a tutor.&#xD;
&#xD;
         11. Concomitant prohibited treatment. Concurrent or planned treatment with strong&#xD;
             inhibitors or strong inducers of cytochrome P450 3A4/5 (see Appendix 6). A one week&#xD;
             wash-out period is necessary for patients who are already on these treatments&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuelle BOMPAS, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO-RenÃ© Gauducheau - St Herblain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Christophe EYMARD, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Jean Godinot - Reims</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guilhem ROUBAUD, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut BergoniÃ© Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe BEUZEBOC, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aline GUILLOT, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de CancÃ©rologie Lucien Neuwirth -ST Priest en Jarez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claude EL KOURI, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Catherine de Sienne - Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank PRIOU, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD VENDEE - La Roche sur Yon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aude FLECHON, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CENTRE LEON BERARD - lyon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Igor LATORZEFF, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karim FIZAZI, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus Grand Paris-Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean BERDAH, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Ste Marguerite - HyÃ¨res</affiliation>
  </overall_official>
  <overall_official>
    <last_name>StÃ©phane CULINE, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>HÃ´pital St Louis - Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sophie ABADIE-LACOURTOISIE, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO - Paul Papin - Angers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe FOURNERET, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de ChambÃ©ry - ChambÃ©ry</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain GRANDGIRARD, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de Mulhouse - mulhouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique BESSON, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Armoricaine de Radiologie - St Brieuc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>LoÃ¯c MOUREY, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius REGAUD - Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain RUFFION, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier Lyon Sud - Pierre BÃ©nite</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tristan MAURINA, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Jean Minoz - BesanÃ§on</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre CLAVERE, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Limoges - Limoges</affiliation>
  </overall_official>
  <overall_official>
    <last_name>VÃ©ronique BECKENDORF, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de CancÃ©rologie de Lorraine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joan Carles, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron - Barcelone</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Riccardo Valdagni, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale dei tumori - Milan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe RONCHIN, Docteur</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre AzurÃ©en de CancÃ©rologie - Mougins</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric LECHEVALLIER, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>HÃ´pital de la conception - Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GwenaÃ«lle GRAVIS, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli Calmettes - Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elise CHAMPEAUX-ORANGE, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR OrlÃ©ans La Source - OrlÃ©ans</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier ARTIGNAN, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint-Gregoire Private Hospital Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne DONEUX, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique GÃ©nÃ©rale d'Annecy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thibaud HAASER, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>HÃ´pital Haut L'EvÃ¨que - Pessac</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Youssef TAZI, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>STRASBOURG ONCOLOGIE LIBERALE - CLINIQUE SAINTE ANNE - Strasbourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>StÃ©phane OUDARD, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL EUROPEEN GEORGES POMPIDOU - Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brigitte LAGUERRE, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CENTRE EUGENE MARQUIS - Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hakim MAHAMMEDI, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CENTRE JEAN PERRIN - Clermont Ferrand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nadine HOUEDE, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de NÃ®mes Caremeau - NÃ®mes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GaÃ«l DEPLANQUE, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Paris Saint Joseph - Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marjorie BACIUCHKA-PALMARO, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>HÃ´pital Nord Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>yazid BELKACEMI, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>HÃ´pital Henri Mondor - CrÃ©teil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mostefa BENNAMOUN, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>L'Institut Mutualiste Montsouris-Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ali HASBINI, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur - Brest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuel GROSS, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>HÃ´pital privÃ© Clairval - Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BÃ©rengÃ¨re NARCISO RAHARIMANANA, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de TOURS HÃ´pital Bretonneau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carole HELISSEY, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>HÃ´pital d'instruction des armÃ©es BÃ©gin - St mandÃ©</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marta GUIX, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital del Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BegoÃ±a PEREZ-VALDERRAMA, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen del Rocio -Sevilla</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrique GALLARDO, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parc Tauli Sabadell Hospital Universitari - Sabadell</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria SAEZ, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Virgen de la Victoria - Malaga</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Montserrat DOMENECH, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Althaia, Xarxa Universitaria i assistencial de Manresa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergio VAZQUEZ ESTEVEZ, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lucus Augusti - Lugo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Miguel Anton APARICIO, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Teresa Herrera - Coruna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria JosÃ© MENDEZ VIDAL, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Reina Sofia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pilar LOPEZ CRIADO, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BegoÃ±a MELLADO GONZALEZ, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco GOMEZ VEIGA, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Salamanca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salvador VILLA i FREIXA, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO Badalona - H.U. Germans Trias</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel CASTELLANO, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario 12 de Octubre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 24, 2013</study_first_submitted>
  <study_first_submitted_qc>September 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2013</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma</keyword>
  <keyword>prostate</keyword>
  <keyword>relapse</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Androgen Deprivation Therapy</keyword>
  <keyword>Cabazitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

